Phase 1/2 Trial Confirms Safety With Repeated Dosing Supporting Further Development in Early-stage Disease and Combination ...
Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus ...
The Nutraceutical Excipients Market was valued at USD 4.5 billion in 2024, reflecting strong expansion driven by the rising consumption of dietary supplements and functional nutrition products. As ...
Targeted therapies and immunotherapies are increasingly offering viable alternatives to the chemotherapies that have stood for decades as a mainstay of treatment for individuals living with blood ...
7hon MSN
Rise of smart skincare at home: How AI, lasers and skin-boosters are becoming everyday beauty tools
Skincare has transformed from a luxury to an accessible, personalised experience with AI, home devices and advanced ...
To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...
An AI-driven computational toolkit, Gcoupler, integrates ligand design, statistical modeling, and graph neural networks to predict endogenous metabolites that allosterically modulate the GPCR–Gα ...
Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive ...
4hon MSN
Rethinking long-term allergy treatments: Experimental vaccine protects against anaphylaxis in mice
Researchers led by the Institut Pasteur, Université Paris, have developed a vaccine that elicits anti-Immunoglobulin E ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback